A phase transition enhances the catalytic activity of SARM1, an NAD(+) glycohydrolase involved in neurodegeneration
Authors
Loring, Heather S.Czech, Victoria L.
Icso, Janneke D.
O'Connor, Lauren C.
Parelkar, Sangram
Byrne, Alexandra B.
Thompson, Paul R
UMass Chan Affiliations
Graduate School of Biomedical SciencesThompson Lab
Byrne Lab
Neurobiology
Program in Chemical Biology
Biochemistry and Molecular Pharmacology
Document Type
Journal ArticlePublication Date
2021-06-29Keywords
C. elegansSARM1
biochemistry
chemical biology
enzymology
kinetics
neuroscience
phase transition
wallerian degeneration
Amino Acids, Peptides, and Proteins
Biochemistry
Enzymes and Coenzymes
Nervous System Diseases
Neuroscience and Neurobiology
UMCCTS funding
Metadata
Show full item recordAbstract
Sterile alpha and toll/interleukin receptor (TIR) motif-containing protein 1 (SARM1) is a neuronally expressed NAD(+) glycohydrolase whose activity is increased in response to stress. NAD(+) depletion triggers axonal degeneration, which is a characteristic feature of neurological diseases. Notably, loss of SARM1 is protective in murine models of peripheral neuropathy and traumatic brain injury. Herein, we report that citrate induces a phase transition that enhances SARM1 activity by ~2000-fold. This phase transition can be disrupted by mutating a residue involved in multimerization, G601P. This mutation also disrupts puncta formation in cells. We further show that citrate induces axonal degeneration in C. elegans that is dependent on the C. elegans orthologue of SARM1 (TIR-1). Notably, citrate induces the formation of larger puncta indicating that TIR-1/SARM1 multimerization is essential for degeneration in vivo. These findings provide critical insights into SARM1 biology with important implications for the discovery of novel SARM1-targeted therapeutics.Source
Loring HS, Czech VL, Icso JD, O'Connor L, Parelkar SS, Byrne AB, Thompson PR. A phase transition enhances the catalytic activity of SARM1, an NAD+ glycohydrolase involved in neurodegeneration. Elife. 2021 Jun 29;10:e66694. doi: 10.7554/eLife.66694. PMID: 34184985; PMCID: PMC8266388. Link to article on publisher's site
DOI
10.7554/eLife.66694Permanent Link to this Item
http://hdl.handle.net/20.500.14038/37989PubMed ID
34184985Related Resources
Rights
Copyright © 2021, Loring et al. This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.Distribution License
http://creativecommons.org/licenses/by/4.0/ae974a485f413a2113503eed53cd6c53
10.7554/eLife.66694
Scopus Count
Except where otherwise noted, this item's license is described as Copyright © 2021, Loring et al. This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.